JAK/TYK2

      Safety data reassuring with UPA 15 mg vs PBO
      No UPA MACE events, low VTE
      Ab#0770
      @RheumNow #ACR24 https://t.co/lMf2dCz2R

      Eric Dein ericdeinmd

      10 months 3 weeks ago
      Safety data reassuring with UPA 15 mg vs PBO No UPA MACE events, low VTE Ab#0770 @RheumNow #ACR24 https://t.co/lMf2dCz2RX https://t.co/3DnPIoVOt8
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA.
      UPA15 + 26-week GC taper

      Jiha Lee JihaRheum

      10 months 3 weeks ago
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r
      Major update in tx for GCA beyond Toci

      SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission wi

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N
      Results from SELECT-GCA➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W

      Mrinalini Dey DrMiniDey

      10 months 3 weeks ago

      Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

      SELECT-GCA: Upa in GCAMerkelUpa 15 mg v 7.5 v PBO w slower GC taper70% new onset, 30% relapse. Few prev on IL6Primar

      Eric Dein ericdeinmd

      10 months 3 weeks ago

      SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

      Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52

      Richard Conway RichardPAConway

      10 months 3 weeks ago
      Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV
      Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work:
      JAKi, TNFi quicker than

      David Liew drdavidliew

      10 months 3 weeks ago
      Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi
      Spatial Proteomics study for TEN

      Marked enrichment of type I and II interferon and STAT1 activation
      Pathways suggests b

      Eric Dein ericdeinmd

      10 months 3 weeks ago
      Spatial Proteomics study for TEN Marked enrichment of type I and II interferon and STAT1 activation Pathways suggests benefit for JAKi in this condition Clinical response in case photos, suggests benefit of pursuing clinical trial Year in Review #ACR24 Bridges @RheumNow https://t.co/K34lbnenRH
      Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulator

      David Liew drdavidliew

      10 months 3 weeks ago
      Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5
      Looking forward to this Plenary - upadacitinib vs plbo in GCA

      Similar to GiACTA, 26wk taper w/UPA better than 52wk tape

      Mike Putman EBRheum

      10 months 3 weeks ago
      Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI
      Rheumatoid,RA,nodules,damage
      Shifting Trends in Initial RA Treatment Approaches
      10 months 3 weeks ago
      A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
      Pain in PsA = predictor of disability and QoL

      TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0
      Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA

      Antoni Chan MD (Prof) synovialjoints

      10 months 3 weeks ago
      Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA
      RheumNow Podcast square
      ACR24 Preview Podcast (11.15.2024)
      10 months 3 weeks ago
      ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.

      Catch up on Conference Podcasts

      ×